• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Open Science

The Open Science Statement of the International Alliance of ALS/MND Associations consists of Values, Principles and Practices as shown in the chart below. The practices are outlined in more detail following the chart.  Our expectation is that any Alliance research collaborators must commit to making their outputs (materials and knowledge) publicly available without restriction on use and adhere to the following values, principles and practices, which support the values of the International Alliance of ALS MND Associations with respect to Open Science.

Values, Principles and Practices

Values Principles Practices
Human-centric
  • Fairness
  • Representative
  • Respectful
  • Inclusive
  • Communications
  • Behaviours
  • PALS/CALS driven
  • Accountability
  • IP
  • Auditable
Knowledge-sharing
  • Urgency
  • Timely
  • Transparency
  • Article access
  • Interoperable
  • Data & code access
  • Replicable & reproducible
  • Protocols
Trustworthy
  • Reliability
  • Accessible documentation
  • Private & secure
  • Compliance processes & guidelines
  • Follow-on research
  • Re-use
  • Attribution & acknowledgement

Practices

  1. Each researcher or project will have a plan for how the principles of Open Science will be adhered to from inception to the end of the project. That plan will include how the values of human centric, the knowledge sharing, and the trustworthiness will be met.
  2. Where possible, existing human data will be used so PALS and CALS do not have to undergo repeat testing if they have made informed consent to make their data available under open science principles.
  3. Post experimental protocols to a protocol-sharing service, such as protocols.io
  4. All articles resulting from funding must be published in a fully open access journal or posted in an open repository with free, immediate readership rights
  5. Researchers will seek to place open access results arising from research projects (internal or collaborative) in the public domain. Researchers will not, under any Alliance Project they undertake (internal or collaborative), file any form of patent application, or allow a collaborator to restrict the research use of Open Access Project Outputs.
  6. Data will be shared according to FAIR principles [Findability, Accessibility, Interoperability, and Reuse of digital assets]
  7. Researchers will promptly release the associated output data through free and publicly accessible digital repositories while still maintaining compliance with any privacy and confidentiality regulations.
  8. Any data, code, and software needed for independent verification of research results must be curated and made free and publicly available in an established, open repository no later than the publication of the first paper based on the data, or no later than the expiration of the grant, whichever comes first.
  9. Research outputs (articles, data, code, and software) resulting from funding must be made available with generous reuse & remixing rights (e.g. CC BY.CCO licences)
  10. Applicants will be encouraged to include the anticipated costs for making their work open in their grant applications.
  11. All researchers and projects will include a data-sharing plan as part of the application process and there will be compliance checkpoints throughout the term of engagement which proactively compiles proof of policy compliance as a component of interim and final reports

Primary Sidebar

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Dick Dayton, USA

    Dick Dayton, USA

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Bob Simonds, USA

    Bob Simonds, USA

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Christian Bär, Germany

    Christian Bär, Germany

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Liam Dwyer, England

    Liam Dwyer, England

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • João Marcos Andrietta, Brazil

    João Marcos Andrietta, Brazil

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Mike Cels, Canada

    Mike Cels, Canada

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Jack Buzby, USA

    Jack Buzby, USA

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Daniela Maria Daverio, Argentina

    Daniela Maria Daverio, Argentina

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Jean Waters, UK

    Jean Waters, UK

  • Paul Launer, USA

    Paul Launer, USA

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • David Solomon, UK

    David Solomon, UK

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login